Emerging Drug Developer: Sonexa Therapeutics

Emerging Drug Developer: Sonexa Therapeutics

Sonexa Therapeutics is just the latest biotech start-up that Eckard Weber has added to his entrepreneurial resume as a partner at Domain Associates. The biotech expert isn't saying much, but he's got great expectations for an early-stage drug Sonexa has in-licensed for Alzheimer's. With $30 million and a few skilled hands in charge of the "semi-virtual" company, Weber believes that Sonexa has the potential to become another winner for Domain--following a business model that has been pursued by more than a dozen companies started under Weber's wing.  

"One of the things we do at Domain is that we look at therapeutic areas which we think are of a particular interest for potential investment and then we go out proactively to look for investment opportunities," Weber tells FierceBiotech. "That includes going out and looking for product opportunities all over the world. And if we find one, we buy or license the product and create a company around the product and make an investment." Article

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.